Biologics Safety Testing Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015 – 2020 and Forecast 2021 – 2027

$ PRICE - $ 3,000.00$ 8,900.00

Biologics Safety Testing Market: By Product Type (Reagents and Kits, Instruments, Services), By Test Type (Sterility Tests, Bioburden Tests, Endotoxin Tests, Residual Host Contamination detection Tests, Cell Line Authentication and Characterization Tests, Others), By Application (Cellular and Gene Therapy, Vaccine and Therapeutics Development, Tissue and Tissue-Related Products Testing, Blood and Blood-Related Products Testing, Stem Cell Research), By End-User (Pharmaceutical Companies, Biotechnology Companies), and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

The global biologics safety testing market size valued USD 3.15 billion in 2020 and expected to reach USD 7.28 billion by 2027, at a CAGR of 12.18% during forecast period 2021 to 2027. Biologics are the large and complex molecules derived from the genes of living organisms by advanced DNA technologies. Biologics are commonly used in the treatment of chronic diseases such as rheumatoid arthritis, cancer, and other chronic diseases. These biologics are complex molecules such as recombinant proteins and monoclonal antibodies among others. Biologics safety testing is carried to ensure the patient safety. Biological safety testing is carried by using various tests such as sterility tests, endotoxins test, residual host contamination detection tests, and bioburden tests among others. Biologics safety testing market exhibiting lucrative growth, which is attributed to increase in the R&D for the development of newer biologics by pharmaceutical and biopharmaceutical companies for the treatment of chronic diseases such as diabetes, cancer and innovation of newer biologics safety tests. Moreover, rise in funding from the government, and increase in the prevalence of chronic diseases are anticipated to fuel the market over the forecast period. Furthermore, acquisitions and mergers, collaborations, and launching of newer tests by market players also immensely boost to the biologics safety testing market. For instance, in June 2016, Charles River Laboratories acquired Blue Stream laboratories to strengthen its capabilities in biologics development and safety assessments. In addition in March 2016, Abreos Biosciences collaborated with True Diagnostics to develop the point-of-care tests for biologics.

Biologics Safety Testing Market

MARKET SUMMARY
-
12.18% CAGR
  • Study Period– 2021 – 2027
  • Base Year– 2020
  • CAGR– 12.18%
  • Largest Market– Europe
  • Fastest Growing Market– North America

Biologics Safety Testing Market

  • The report on global biologics safety testing market gives historical, current and future market sizes (US$ Mn) based on product type, test type, application, end users and geographical regions.
  • biologics safety testing market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Key Players
  • Thermo Fisher Scientific Inc.
  • WuXi Apptec
  • Sartorius AG
  • Toxikon Corporation
  • Cytovance Biologics, Inc.
  • SGS SA
Biologics Safety Testing Market

Drivers And Restraints

Growing biologic products launches, rise R&D activities by pharmaceutical and biotechnology companies, technological advancements of biologics safety testing methods, stringent regulatory guidelines for product approval, and rise in funding from public and private sectors for the development of newer biologics are exepcted to boost the biologics safety testing market over the forecast period. However, high cost of biologics safety testing, and lack of well-developed healthcare in underdeveloped countries are hamper the growth of biologics safety testing market.


North-America got significant share

Biologics Safety Testing Market

Geographically, global biologics safety testing market segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America biologics safety testing market expected to hold dominant share owing to increase in R&D activities by the market players, presence of huge number of market players, and well-developed healthcare infrastructure. Europe biologics safety testing market has a significant share owing to adoption of newer technologies, expansion of business by market players in Germany and UK, and increase in funding for R&D activities for the development of newer biologics. For instance, in 2013, European Research Council awarded $830 Mn for life sciences research in Europe. Asia Pacific biologics safety testing market is projected to grow due to rise in awareness about biologics safety testing, favorable regulatory policies, and increase in healthcare expenditure.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Notable Market Developments

  • In October 2017, Sterigenics International LLC acquired Toxikon’s European laboratory business including biologics testing business

Key

Key Features of the Report

Biologics Safety Testing Market Segmentation


Location

GEOGRAPHY


Report

Table Of Content


Report

Company Profile

  • Charles River Laboratories (U.S.),
  • Pace Analytical Services Inc. (U.S.)
  • Thermo Fisher Scientific Inc. (U.S.)
  • WuXi Apptec (China)
  • Sartorius AG (Germany)
  • Toxikon Corporation (U.S.)
  • Cytovance Biologics, Inc. (U.S.)
  • SGS SA (Switzerland)
  • Merck KGaA (Germany)
  • Sterigenics International, LLC (U.S.)
  • Abreos Biosciences (U.S.)
  • True Diagnostics, Inc. (U.S.)

Description

The global biologics safety testing market size valued USD 3.15 billion in 2020 and expected to reach USD 7.28 billion by 2027, at a CAGR of 12.18% during forecast period 2021 to 2027. Biologics are the large and complex molecules derived from the genes of living organisms by advanced DNA technologies. Biologics are commonly used in the treatment of chronic diseases such as rheumatoid arthritis, cancer, and other chronic diseases. These biologics are complex molecules such as recombinant proteins and monoclonal antibodies among others. Biologics safety testing is carried to ensure the patient safety. Biological safety testing is carried by using various tests such as sterility tests, endotoxins test, residual host contamination detection tests, and bioburden tests among others. Biologics safety testing market exhibiting lucrative growth, which is attributed to increase in the R&D for the development of newer biologics by pharmaceutical and biopharmaceutical companies for the treatment of chronic diseases such as diabetes, cancer and innovation of newer biologics safety tests. Moreover, rise in funding from the government, and increase in the prevalence of chronic diseases are anticipated to fuel the market over the forecast period. Furthermore, acquisitions and mergers, collaborations, and launching of newer tests by market players also immensely boost to the biologics safety testing market. For instance, in June 2016, Charles River Laboratories acquired Blue Stream laboratories to strengthen its capabilities in biologics development and safety assessments. In addition in March 2016, Abreos Biosciences collaborated with True Diagnostics to develop the point-of-care tests for biologics.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX